Chugai Pharmaceutical Co., Ltd., along with its affiliated entities, is a global pharmaceutical company deeply involved in the discovery, development, production, marketing, and distribution of medicines. Its diverse product portfolio addresses a range of therapeutic areas. Key cancer treatments include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. For osteoporosis, it offers Actemra, Edirol, and Bonviva. Renal conditions are treated with products such as Mircera and Oxarol. Furthermore, its lineup for neurological and other diverse ailments features Hemlibra, CellCept, and Enspryng. The company maintains an active pipeline of investigational therapies across areas like oncology, musculoskeletal disorders, autoimmune diseases, kidney issues, neurological conditions, and other health concerns. Chugai benefits from strategic partnerships with the Roche Group and collaborates on research projects with academic institutions. Established in Tokyo, Japan, in 1925, Chugai Pharmaceutical Co., Ltd. functions as a subsidiary of Roche Holding Ltd.
